Literature DB >> 12695909

Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer.

L M Berstein1, A E Tchernobrovkina, V B Gamajunova, A J Kovalevskij, D A Vasilyev, O F Chepik, E A Turkevitch, E V Tsyrlina, S J Maximov, L A Ashrafian, J H H Thijssen.   

Abstract

OBJECTIVES: To compare estrogen concentrations in endometrial cancer tissue with those in macroscopically normal endometrium and with certain morphological characteristics of the tumor and endocrine parameters in patients.
METHODS: The estradiol content was evaluated by radioimmunoassay after homogenization and extraction in 78 adenocarcinomas (61 from postmenopausal patients).
RESULTS: Higher concentrations of estradiol in tumor tissue samples than in macroscopically normal endometrium were found in patients of both reproductive and postmenopausal age. This difference was the same in patients with either endometrial carcinoma type I or type II. No association between tumor steroid receptor levels, estradiol concentrations in blood serum, and timing of menopause with intratumoral estradiol contents was discovered. Estradiol concentrations in tumor tissues correlated positively with the clinical stage of disease and rate of tumor invasion (in patients with peripheric/lower type of fat topography), and negatively with tumor differentiation stage (in patients with central/upper type of fat topography) and the percentage of intact double-stranded DNA in normal endometrium.
CONCLUSIONS: Tumor estrogen content in endometrial cancer has clinical significance that is modified in the presence of certain endocrine characteristics related to insulin resistance. The role of local estrogen production (aromatase activity) in this setting deserves special study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695909     DOI: 10.1007/s00432-003-0427-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  24 in total

Review 1.  Recent data about endometrial carcinoma: potential of anti-aromatase agents.

Authors:  J Bonte
Journal:  Eur J Gynaecol Oncol       Date:  2001       Impact factor: 0.196

Review 2.  Obesity, insulin, sex steroids and ovulation.

Authors:  J E Nestler
Journal:  Int J Obes Relat Metab Disord       Date:  2000-06

Review 3.  Estrogen and endometrial cancer: an epilogue à la recherche du temps perdu.

Authors:  S B Gusberg
Journal:  Gynecol Oncol       Date:  1994-01       Impact factor: 5.482

4.  Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.

Authors:  Lev Berstein; Sergei Maximov; Eduard Gershfeld; Irina Meshkova; Vera Gamajunova; Evgenia Tsyrlina; Alexei Larionov; Anatolii Kovalevskij; Dmitry Vasilyev
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2002-11-15       Impact factor: 2.435

Review 5.  Hormonal interactions in endometrial cancer.

Authors:  G Emons; G Fleckenstein; B Hinney; A Huschmand; W Heyl
Journal:  Endocr Relat Cancer       Date:  2000-12       Impact factor: 5.678

6.  Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer.

Authors:  K Naitoh; H Honjo; T Yamamoto; M Urabe; Y Ogino; T Yasumura; T Nambara
Journal:  J Steroid Biochem       Date:  1989-12       Impact factor: 4.292

7.  Estrogen content and DNA unwinding in tumor and normal endometrial tissue of aging endometrial cancer patients.

Authors:  L M Berstein; E V Bakhidze; T P Evtushenko; V B Gamajunova; O G Krjukova; I G Kovalenko; E V Tsyrlina
Journal:  Mutat Res       Date:  1996-09-23       Impact factor: 2.433

8.  CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors.

Authors:  S E Bulun; K Economos; D Miller; E R Simpson
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

9.  Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging.

Authors:  P Bolufer; E Ricart; A Lluch; C Vazquez; A Rodriguez; A Ruiz; F Llopis; J Garcia-Conde; R Romero
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

10.  Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study.

Authors:  A Zeleniuch-Jacquotte; A Akhmedkhanov; I Kato; K L Koenig; R E Shore; M Y Kim; M Levitz; K R Mittal; U Raju; S Banerjee; P Toniolo
Journal:  Br J Cancer       Date:  2001-04-06       Impact factor: 7.640

View more
  24 in total

1.  Proliferation and cell-cell fusion of endometrial carcinoma are induced by the human endogenous retroviral Syncytin-1 and regulated by TGF-beta.

Authors:  Reiner Strick; Sven Ackermann; Manuela Langbein; Justine Swiatek; Steffen W Schubert; Said Hashemolhosseini; Thomas Koscheck; Peter A Fasching; Ralf L Schild; Matthias W Beckmann; Pamela L Strissel
Journal:  J Mol Med (Berl)       Date:  2006-10-26       Impact factor: 4.599

2.  Expression and in vitro functions of the ghrelin axis in endometrial cancer.

Authors:  Jenny N T Fung; Inge Seim; Dengfeng Wang; Andreas Obermair; Lisa K Chopin; Chen Chen
Journal:  Horm Cancer       Date:  2010-10       Impact factor: 3.869

3.  PCOS and obesity: insulin resistance might be a common etiology for the development of type I endometrial carcinoma.

Authors:  Xin Li; Ruijin Shao
Journal:  Am J Cancer Res       Date:  2014-01-15       Impact factor: 6.166

4.  The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer.

Authors:  Paul A Foster; L W Lawrence Woo; Barry V L Potter; Michael J Reed; Atul Purohit
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

5.  Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer.

Authors:  L M Berstein; J O Kvatchevskaya; T E Poroshina; I G Kovalenko; E V Tsyrlina; T S Zimarina; A F Ourmantcheeva; L Ashrafian; J H H Thijssen
Journal:  J Cancer Res Clin Oncol       Date:  2004-11       Impact factor: 4.553

6.  Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice.

Authors:  Taija Saloniemi; Päivi Järvensivu; Pasi Koskimies; Heli Jokela; Tarja Lamminen; Sadaf Ghaem-Maghami; Roberto Dina; Pauliina Damdimopoulou; Sari Mäkelä; Antti Perheentupa; Harry Kujari; Jan Brosens; Matti Poutanen
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

7.  Aromatase excess in cancers of breast, endometrium and ovary.

Authors:  Serdar E Bulun; Dong Chen; Meiling Lu; Hong Zhao; Youhong Cheng; Masashi Demura; Bertan Yilmaz; Regina Martin; Hiroki Utsunomiya; Steven Thung; Emily Su; Erica Marsh; Amy Hakim; Ping Yin; Hiroshi Ishikawa; Sanober Amin; Gonca Imir; Bilgin Gurates; Erkut Attar; Scott Reierstad; Joy Innes; Zhihong Lin
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

8.  Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: a novel therapeutic target.

Authors:  Ryoichi Asaka; Tsutomu Miyamoto; Yasushi Yamada; Hirofumi Ando; David Hamisi Mvunta; Hisanori Kobara; Tanri Shiozawa
Journal:  Lab Invest       Date:  2015-09-14       Impact factor: 5.662

9.  Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha.

Authors:  Frances Collins; Sheila MacPherson; Pamela Brown; Vincent Bombail; Alistair R W Williams; Richard A Anderson; Henry N Jabbour; Philippa T K Saunders
Journal:  BMC Cancer       Date:  2009-09-16       Impact factor: 4.430

10.  A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells.

Authors:  Sheng-Li Lin; Li-Ying Yan; Xing-Wei Liang; Zhen-Bo Wang; Zhao-Yi Wang; Jie Qiao; Heide Schatten; Qing-Yuan Sun
Journal:  Reprod Biol Endocrinol       Date:  2009-09-24       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.